|  | Died | | | Survived | | | Overall | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Solid cancer (N=765) | Metastasized cancer (N=909) | Hematological cancer (N=532) | Solid cancer (N=2513) | Metastasized cancer (N=1259) | Hematological cancer (N=1103) | Solid cancer (N=3278) | Metastasized cancer (N=2168) | Hematological cancer (N=1635) |
| **Renal Replacement Therapy** |  |  |  |  |  |  |  |  |  |
| Received | 93 (12.2%) | 74 (8.1%) | 89 (16.7%) | 145 (5.8%) | 32 (2.5%) | 97 (8.8%) | 238 (7.3%) | 106 (4.9%) | 186 (11.4%) |
| **Mechanic Ventilation** |  |  |  |  |  |  |  |  |  |
| Received | 426 (55.7%) | 400 (44.0%) | 296 (55.6%) | 900 (35.8%) | 377 (29.9%) | 338 (30.6%) | 1,326 (40.5%) | 777 (35.8%) | 634 (38.8%) |
| **Vasopressor(s)** |  |  |  |  |  |  |  |  |  |
| Received | 503 (65.8%) | 493 (54.2%) | 343 (64.5%) | 1,012 (40.3%) | 445 (35.3%) | 443 (40.2%) | 1,515 (46.2%) | 938 (43.3%) | 786 (48.1%) |
| **Race** |  |  |  |  |  |  |  |  |  |
| Asian | 18 (2.4%) | 58 (6.4%) | 14 (2.6%) | 67 (2.7%) | 54 (4.3%) | 23 (2.1%) | 85 (2.6%) | 112 (5.2%) | 37 (2.3%) |
| Black | 92 (12.0%) | 109 (12.0%) | 47 (8.8%) | 225 (9.0%) | 105 (8.3%) | 111 (10.1%) | 317 (9.7%) | 214 (9.9%) | 158 (9.7%) |
| Hispanic | 38 (5.0%) | 31 (3.4%) | 22 (4.1%) | 123 (4.9%) | 48 (3.8%) | 45 (4.1%) | 161 (4.9%) | 79 (3.6%) | 67 (4.1%) |
| Other | 85 (11.1%) | 87 (9.6%) | 69 (13.0%) | 200 (8.0%) | 91 (7.2%) | 86 (7.8%) | 285 (8.7%) | 178 (8.2%) | 155 (9.5%) |
| White | 532 (69.5%) | 624 (68.6%) | 380 (71.4%) | 1,898 (75.5%) | 961 (76.3%) | 838 (76.0%) | 2,430 (74.1%) | 1,585 (73.1%) | 1,218 (74.5%) |